Print Page  Close Window
8-K
PARATEK PHARMACEUTICALS, INC. filed this Form 8-K on 01/04/2019
Entire Document
 

Slide 38

Clinical Success at PTE Baseline Pathogen (OASIS-2) Highly Effective Across Key Gram (+) Skin Pathogens Omadacycline (n=276) Linezolid (n=287) Baseline Pathogen N Clinical Success n (%) N Clinical Success n (%) Staphylococcus aureus 220 182 (82.7) 233 186 (79.8) MRSA 104 89 (85.6) 107 85 (79.4) MSSA 120 97 (80.8) 130 103 (79.2) Staphylococcus lugdunensis 5 4 (80.0) 0 0 Streptococcus pyogenes 29 20 (69.0) 16 9 (56.3) Streptococcus anginosus group 57 49 (86.0) 45 33 (73.3) Streptococcus anginosus 27 24 (88.9) 20 16 (80.0) Streptococcus intermedius 23 18 (78.3) 24 16 (66.7) Streptococcus constellatus 9 8 (88.9) 7 5 (71.4) Enterococcus faecalis 8 8 (100.0) 12 9 (75.0) VRE 0 0 2 2 (100.0) VSE 7 7 (100.0) 10 7 (70.0)